<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31872047</article-id>
<article-id pub-id-type="pmc">6878838</article-id>
<article-id pub-id-type="publisher-id">NG2019010843</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000370</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>91</subject>
<subject>228</subject>
<subject>235</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>CNS manifestations in patients with telomere biology disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bhala</surname>
<given-names>Sonia</given-names>
</name>
<degrees>BS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-4467-1725</contrib-id>
<name>
<surname>Best</surname>
<given-names>Ana F.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Postdoctoral fellow at NIH NCI DCEG BB during this research. Currently employed at NIH NCI DCTD BRP BB.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giri</surname>
<given-names>Neelam</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alter</surname>
<given-names>Blanche P.</given-names>
</name>
<degrees>MD, MPH</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>National Cancer Institute</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Fanconi Anemia Research Fund</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pao</surname>
<given-names>Maryland</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>I am an ex officio member of the NIMH DSMB. I am a federal employee and this is part of my official duties.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>I am an Associate Editor of Psychosomatics. This is an unpaid position.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>I am a Federal employee for the past 17 years.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gropman</surname>
<given-names>Andrea</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>National Urea cycle foundation PRISMS (parents and researchers interested in Smith Magenis syndrome)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>National Urea cycle foundation, funding to speak at yearly parent/family conference</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Editorial board, Journal of Child Neurology 2016-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>Swaiman's Pediatric Neurlogy, 6th edition, Elsevier, 6th edition, 2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NICHD/NCATS U54 HD061221, P.I. 2014-2019 NICHD/NCATS U54 HD061221 15S1,P.I. 2018-2019</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Urea cycle foundation Propionic acidemia foundation O'Malley Foundations</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Marriott International, employee stock options, spouse Bioreference Laboratories, employee stock options, spouse</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7347-2170</contrib-id>
<name>
<surname>Baker</surname>
<given-names>Eva H.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Intramural research program of the National Institutes of Health</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-6006-0740</contrib-id>
<name>
<surname>Savage</surname>
<given-names>Sharon A.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Intramural research program, National Cancer Institute</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Clinical Genetics Branch (S.B., N.G., B.P.A., S.A.S.) and Biostatistics Branch (A.F.B.), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville; Office of the Clinical Director (M.P.), National Institute of Mental Health, National Institutes of Health, Bethesda, MD; Department of Neurology (A.G.), Children's National Medical Center, Washington, DC; and Department of Radiology and Imaging Sciences (E.H.B.), Clinical Center, National Institutes of Health, Bethesda, MD.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Correspondence</bold> Dr. Savage <email>savagesh@mail.nih.gov</email></corresp>
<fn fn-type="financial-disclosure">
<p>Go to <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e370/tab-article-info">Neurology.org/NG</ext-link> for full disclosures. Funding information is provided at the end of the article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The Article Processing Charge was funded by the NIH.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>10</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>6</issue>
<elocation-id>370</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2019010843.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective</title>
<p>We systematically evaluated CNS manifestations in patients with inherited telomere biology disorders (TBDs) to better understand the clinical and biological consequences of germline aberrations in telomere biology.</p>
</sec>
<sec>
<title>Methods</title>
<p>Forty-four participants with TBDs (31 dyskeratosis congenita, 12 Hoyeraal-Hreidarsson syndrome, and 1 Revesz syndrome) enrolled in an institutional review board–approved longitudinal cohort study underwent detailed clinical assessments, brain MRI, and genetic testing. Lymphocyte telomere length Z-scores were calculated to adjust for age.</p>
</sec>
<sec>
<title>Results</title>
<p>In this cohort, 25/44 (57%) patients with a TBD had at least 1 structural brain abnormality or variant, most commonly cerebellar hypoplasia (39%). Twenty-one patients (48%) had neurodevelopmental disorder or psychomotor abnormality. Twelve had psychiatric diagnoses, including depression and/or anxiety disorders. Other findings such as hypomyelination, prominent cisterna magna, and cavum septum pellucidum were more frequent than in the general population (<italic>p</italic> &lt; 0.001). Shorter lymphocyte telomere length was associated with an increased number of MRI findings (<italic>p</italic> = 0.02) and neurodevelopmental abnormalities (<italic>p</italic> &lt; 0.001). Patients with autosomal recessive or X-linked TBDs had more neurologic findings than those with autosomal dominant disease.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Structural brain abnormalities and variants are common in TBDs, as are neurologic and psychiatric symptoms. The connection between neurodevelopment and telomere biology warrants future study.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>Intramural Research Programs of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, the National Institute of Mental Health</funding-source>
<award-id>ZIA MH002922-11</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Telomere biology disorders (TBDs) comprise a spectrum of illnesses caused by pathogenic germline variants in telomere biology genes resulting in very short telomeres.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup> Dyskeratosis congenita (DC) is the prototypic TBD characterized by the mucocutaneous triad of reticulate skin pigmentation, nail dystrophy, and oral leukoplakia. Patients with DC have high rates of bone marrow failure (BMF), cancer, pulmonary disease, liver fibrosis, and other medical problems.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R4">4</xref></sup> Subsets of DC include Hoyeraal-Hreidarsson (HH) syndrome with associated cerebellar hypoplasia, microcephaly, neurodevelopmental disorder, intrauterine growth restriction (IUGR), and immune deficiency and Revez syndrome (RS), which involves bilateral exudative retinopathy, intracranial calcifications, neurodevelopmental disorder, and IUGR. While DC usually manifests in childhood, adult-onset TBDs occur often with isolated aplastic anemia or pulmonary fibrosis.</p>
<p>Very short lymphocyte telomeres for age measured by flow fluorescence in situ hybridization (flow FISH) are diagnostic of DC/TBDs.<sup><xref ref-type="bibr" rid="R5">5</xref></sup> Pathogenic germline variants in at least 14 telomere biology genes have been implicated in TBD pathogenesis: autosomal dominant (AD) (<italic>TERT, TERC, RTEL1, PARN, TINF2, ACD,</italic> and <italic>NAF1</italic>), autosomal recessive (AR) (<italic>TERT, RTEL1, PARN, ACD, CTC1, WRAP53, NOP10, NHP2, POT1,</italic> and <italic>STN</italic>), and X-linked recessive (XLR) (<italic>DKC1</italic>) inheritance.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup> About 70% of patients with classic DC have a known genetic cause.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup></p>
<p>Previous studies suggest that 10%–50% of patients with DC have CNS involvement.<sup><xref ref-type="bibr" rid="R6">6</xref><xref ref-type="bibr" rid="R7">–</xref><xref ref-type="bibr" rid="R8">8</xref></sup> In this study, we systematically evaluated patients with TBDs who underwent brain MRIs and neurologic and psychiatric evaluations to better understand the CNS manifestations of aberrant telomere biology.</p>
<sec id="s1" sec-type="methods">
<title>Methods</title>
<sec id="s1-1">
<title>Standard protocol approvals, registrations, and patient consents</title>
<p>Individuals in this study were participants in the National Cancer Institute's Institutional Review Board–approved longitudinal cohort study “Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes” (NCT-00027274, <ext-link ext-link-type="uri" xlink:href="https://marrowfailure.cancer.gov">marrowfailure.cancer.gov</ext-link>,<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup>). All patients or their legal guardians provided written informed consent.</p>
</sec>
<sec id="s1-2">
<title>Study participants and clinical evaluations</title>
<p>We evaluated 44 patients, from 36 families, with DC, HH, or RS including 26 children and 18 adults. Adults were defined as individuals who were aged 18 years or older on the date of their MRI. Regardless of their symptoms, all patients in this report underwent complete physical examination, and neurologic and psychiatric assessments conducted and/or reviewed by the authors at the NIH Clinical Center between 2001 and 2015. They also underwent a brain MRI, which was performed and/or interpreted at the NIH Clinical Center.</p>
<p>Brain MRIs from both NIH (n = 31) and other institutions (n = 13) were reviewed by the neuroradiologist (E.H.B.). Structural abnormalities and minor variations were recorded. Findings we considered to be abnormalities included cerebellar hypoplasia, delayed myelination, white matter lesions, moderate or marked prominence of the cisterna magna, atrophy, and hypoplasia of the corpus callosum. Findings we considered to be minor variations included mild prominence of the cisterna magna, cavum septum pellucidum and/or cavum vergae, intraparenchymal cysts, and localized prominence of portions of the lateral ventricles (minor colpocephaly). In differentiating cerebellar atrophy from cerebellar hypoplasia, we considered it to be atrophy if the sulci were more prominent than normal, whereas the absence or disproportionately small size of part or all of the cerebellum without prominent sulci was considered to be hypoplasia; in some cases, both findings were present. Delayed myelination could only be evaluated in the youngest children in the study group.</p>
<p>Neurologic findings were divided into 2 categories: neurodevelopmental disorder that included speech and language delay, learning difficulties, and severe neurodevelopmental disorder, or neuromotor findings including difficulties with speech articulation, ataxia, incoordination, and/or an abnormal gait. Microcephaly was defined as head circumference less than the 5th percentile for age per Centers for Disease Control guidelines<sup><xref ref-type="bibr" rid="R11">11</xref></sup> and analyzed as an independent category. The presence of a <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> (<italic>DSM</italic>)<italic>-IV</italic><sup><xref ref-type="bibr" rid="R12">12</xref></sup> (evaluations before 2013) or DSM-5<sup><xref ref-type="bibr" rid="R13">13</xref></sup> (evaluations after 2013) psychiatric diagnosis was also assessed as its own category. Ten of the patients included in this study were also included in our previous study.<sup><xref ref-type="bibr" rid="R8">8</xref></sup></p>
<p>Flow FISH lymphocyte telomere length was measured in 41 patients as part of the diagnostic workup for DC; 3 patients did not have telomere length test results available. Lymphocyte telomere length was adjusted for age by calculating Z-scores.<sup><xref ref-type="bibr" rid="R14">14</xref></sup> The degree of BMF was classified as severe, moderate, or none by standard definitions.<sup><xref ref-type="bibr" rid="R5">5</xref></sup> Three patients underwent hematopoietic cell transplantation before their MRI and clinical evaluation at the NIH Clinical Center. Clinical genetic testing identified the causative gene in 38 of the 44 patients (<xref ref-type="table" rid="T1">table 1</xref>). Patients with HH and RS, indicated as HH/RS, were combined for analyses. We grouped patients by gene and inheritance patterns (XLR/AR, AD, and <italic>TINF2</italic>) as previously described.<sup><xref ref-type="bibr" rid="R15">15</xref></sup></p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Clinical and genetic characteristics of study participants</p>
</caption>
<graphic xlink:href="NG2019010843t1"></graphic>
</table-wrap>
</sec>
<sec id="s1-3">
<title>Statistical methods</title>
<p>The correlations between clinical findings were tested with the Pearson correlation coefficient. Fisher exact tests were used to compare the relative prevalence of features across inheritance pattern groups, as well as between our cohort and previously reported incidental findings in a healthy pediatric population.<sup><xref ref-type="bibr" rid="R16">16</xref></sup> Binomial logistic regression models were used to compare other clinical features with number of MRI structural, neurologic, and psychiatric abnormalities. Linear regression models were used to determine effect size between telomere length Z-scores and the number of MRI/neurologic abnormalities. We controlled for sex, age, and/or inheritance pattern in these analyses, based on the finding(s) being evaluated. Inheritance patterns considered were XLR, AD, and AR. Statistical analysis was performed with R Version 3.4.0 and the Excel Analysis ToolPak (Microsoft Office 2017).</p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2-1">
<title>Patient demographics</title>
<p>The characteristics of the study participants are shown in <xref ref-type="table" rid="T1">table 1</xref>. Thirty-one individuals had clinical DC, 12 had HH, and 1 had RS. There were 6 sibling pairs. Two of these siblings also had an affected parent. Patient age at the time of brain MRI ranged from 1 to 60 years (median 15 years) and was skewed toward younger ages (<italic>p</italic> = 0.004) with 59% pediatric patients. The TBD-associated pathogenic germline variant was known in 38 of 44 patients and included <italic>TINF2, DKC1</italic>, <italic>TERT</italic>, <italic>TERC</italic>, <italic>RTEL1</italic>, <italic>PARN</italic>, <italic>ACD</italic>, and <italic>WRAP53</italic>.</p>
</sec>
<sec id="s2-2">
<title>Structural brain abnormalities and variants</title>
<p>One or more brain MRI abnormalities were present in 25 of the 44 patients (57%) (<xref ref-type="table" rid="T2">table 2</xref>, <xref ref-type="fig" rid="F1">figure 1</xref>). The maximum number of abnormal findings on brain MRI was 4, seen in 3 patients with DC. All 3 of these patients possessed a recessive genotype and presented with severe BMF. Seventeen patients had cerebellar hypoplasia, 8 had cerebral atrophy, 8 had periventricular cysts, and 7 had a corpus callosum abnormality. In 10 patients with cerebellar hypoplasia, cerebellar atrophy was also noted. Five of the 17 patients with cerebellar hypoplasia had a small pons. Delayed myelination could not be assessed in all the patients because of the cross-sectional nature of the study; however, 6 patients between the ages 1.2–6.5 years (median 3.6 years) had findings consistent with delayed myelination.</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>CNS findings by age and mode of inheritance in patients with TBDs</p>
</caption>
<graphic xlink:href="NG2019010843t2"></graphic>
</table-wrap>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Telomere length associations with structural brain abnormalities and neurologic manifestations</title>
<p>(A) The number of structural abnormalities on brain MRI and telomere length Z-scores. A 1-unit decrease in the telomere Z-score was associated with 0.47 more structural abnormalities (<italic>p</italic> = 0.018, 95% confidence interval [CI] 0.09–0.85). (B) Neurologic manifestations and telomere length Z-scores. A 1-unit decrease in the telomere Z-score was associated with 0.89 more neurologic abnormalities (<italic>p</italic> &lt; 0.001, 95% CI 0.42–1.35).</p>
</caption>
<graphic xlink:href="NG2019010843f1"></graphic>
</fig>
<p>Brain MRI findings were correlated with the number of other TBD-related features. Patients with a higher number of MRI findings were more likely to have shorter telomeres than those with a lower number or no findings (<italic>p</italic> = 0.02) (<xref ref-type="fig" rid="F2">figure 2</xref>). The XLR/AR inheritance patterns had higher frequencies of cerebellar hypoplasia than all other inheritance patterns combined (odds ratio [OR] = 6.6, 95% confidence interval [CI] 1.71–30.96, <italic>p</italic> = 0.009), after controlling for sex and age group (pediatric vs adult). Those with severe BMF had higher frequencies of cerebellar hypoplasia (OR = 13.35, 95% CI 2.46–111.68, <italic>p</italic> = 0.006) than patients with nonsevere or no BMF, controlling for sex and inheritance pattern. Patients with severe BMF also had higher frequencies of MRI findings (OR = 8.4, 95% CI 3.12–27.80, <italic>p</italic> = 0.001) than those with nonsevere BMF.</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Cerebellar hypoplasia exists in telomere biology disorders at varying levels of severity</title>
<p>(A) Seventeen-month-old boy with heterozygous pathogenic <italic>RTEL1</italic> variant, severe bone marrow failure, microcephaly, severe neurodevelopmental disorder, and truncal ataxia. (B) Three-year-old affected brother of A with mild cytopenia, microcephaly, ataxia, and global neurodevelopmental and speech disorders. (C) Ten-year-old boy with pathogenic <italic>DKC1</italic> variant. He had the mucocutaneous triad, microcephaly, esophageal and meatal strictures, incoordination, and progressive bone marrow failure needing treatment by age 10 years. (D) Normal cerebellum and mild prominence of cisterna magna in a 15-year-old girl with dyskeratosis congenita (DC) due to <italic>TERC</italic> pathogenic variant. (E) Normal size cerebellum and cisterna magna in a 3-year-old boy with DC due to <italic>TINF2</italic> pathogenic variant. (F) Bilateral periventricular cystic leukomalacia adjacent to the ventricular trigones in a 6-year-old boy with <italic>TINF2</italic> pathogenic variant. Arrow indicates cerebellar abnormalities.</p>
</caption>
<graphic xlink:href="NG2019010843f2"></graphic>
</fig>
<p>Several brain MRI findings in our patients occurred at much higher frequencies than found incidentally in a general pediatric population.<sup><xref ref-type="bibr" rid="R16">16</xref></sup> The statistically significant (<italic>p</italic> &lt; 0.001) findings included higher frequencies of corpus callosum abnormalities, prominent cisterna magna, white matter lesions, and cavum septum pellucidum, and/or cavum vergae variants (<xref ref-type="table" rid="T3">table 3</xref>). Twenty patients in our study had minor colpocephaly.</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>Incidental findings on brain imaging in the general pediatric population in comparison with brain MRI findings in patients with TBDs</p>
</caption>
<graphic xlink:href="NG2019010843t3"></graphic>
</table-wrap>
</sec>
<sec id="s2-3">
<title>Microcephaly</title>
<p>Microcephaly (head circumference &lt; 5th percentile) was present in 17 of 44 patients (<xref ref-type="table" rid="T2">table 2</xref>, <xref ref-type="fig" rid="F3">figure 3</xref>). The median head circumference for all patients, adjusted for age and sex, was at the 29th percentile. Our data showed a bimodal distribution of head circumference, suggesting that head circumference was either severely affected or unaffected. Fourteen of the 17 patients with microcephaly had head circumferences at or below the 1st percentile. Patients with microcephaly had significantly shorter telomeres than those without microcephaly (<italic>p</italic> = 0.002). Pediatric patients had a higher frequency of microcephaly than adult patients (OR = 4.50, 95% CI 1.15–21.1, <italic>p</italic> = 0.04) after controlling for sex and inheritance pattern. Patients with HH/RS had a higher frequency of microcephaly than patients with clinical DC (OR = 9.24, 95% CI 1.98–55.02, <italic>p</italic> = 0.01), after controlling for age, sex, and inheritance pattern.</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>Head circumference by gene of 43 patients with telomere biology disorders</title>
<p>(A) Males. (B) Females. There was also one 19-month-old patient in the study with microcephaly who is not shown because of lack of exact measurements.</p>
</caption>
<graphic xlink:href="NG2019010843f3"></graphic>
</fig>
</sec>
<sec id="s2-4">
<title>Neurologic findings</title>
<p>Neurologic abnormalities were present in 21/44 patients (<xref ref-type="table" rid="T2">table 2</xref>). Nineteen had neurodevelopmental disorder. There were 16 patients with impaired neuromotor functioning, such as abnormal gait (15/44), dysarthria (14/44), incoordination (13/44), and ataxia (12/44). Pediatric patients were more likely to have neuromotor impairments than adult patients (OR = 10.2, 95% CI 2.20–68.1, <italic>p</italic> = 0.007). Patients with HH/RS were more likely to have neurodevelopmental disorder (OR = 20.5, 95% CI 2.1–621.2, <italic>p</italic> = 0.025) and neuromotor impairment (OR = 32.2, 95% CI 5.8–283.7, <italic>p</italic> = 0.0003) than patients with DC. Although all patients with DC had short telomeres, those with neurodevelopmental disorder, neuromotor impairment, and higher numbers of neurologic findings overall had much shorter telomeres than patients without these features (<italic>p</italic> = 0.005, <italic>p</italic> = 0.004, and <italic>p</italic> ≤ 0.001, respectively) (<xref ref-type="fig" rid="F1">figure 1B</xref>). Patients with AR/XLR pathogenic variants were more likely to have neurologic findings than those with AD disease (<italic>p</italic> = 0.03). Those with severe BMF had a significantly higher frequency of neurodevelopmental disorder than patients with nonsevere or no BMF (OR = 10.6, 95% CI 1.81–97.03, <italic>p</italic> = 0.02) and tended to have a higher frequency of neuromotor impairment (OR = 5.5, 95% CI 1.19–32.73, <italic>p</italic> = 0.04).</p>
</sec>
<sec id="s2-5">
<title>Psychiatric findings</title>
<p>A clinically significant psychiatric diagnosis was identified in 12 of 44 patients. The majority of the psychiatric diagnoses were mood disorders in adults with depression (n = 6) and/or anxiety/panic attacks (n = 3), autism spectrum disorder (n = 2), and bipolar disorder (n = 1). The frequency of psychiatric findings was similar between the inheritance patterns (<xref ref-type="table" rid="T2">table 2</xref>).</p>
</sec>
<sec id="s2-6">
<title>Overall</title>
<p>Microcephaly was associated with an increased number of structural MRI findings (r = 0.42, <italic>p</italic> = 0.004). Microcephaly and cerebellar hypoplasia strongly correlated with neurodevelopmental disorder (r = 0.62, <italic>p</italic> &lt; 0.0001) and neuromotor deficits (r = 0.7, <italic>p</italic> &lt; 0.001) such as ataxia, incoordination, and dysarthria. Five of 17 patients with cerebellar hypoplasia did not present with neuromotor cerebellar findings. Of these 5, 3 did not present with neurodevelopmental disorder either and were considered neurologically asymptomatic. Abnormal CNS findings were primarily seen in the pediatric patients with severe BMF who had the shortest telomeres and were also associated with XLR/AR inheritance or <italic>TINF2</italic> variants. Four of the 6 sibling pairs with XLR/AR disease (<italic>DKC1</italic> and <italic>RTEL1</italic>) had overlapping CNS features including abnormal MRIs and neurodevelopmental disorder. No CNS abnormalities were present in 1 sibling each in sibling pairs with disease due to <italic>TINF2</italic> and 1 with <italic>DKC1</italic>.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>In addition to the classic mucocutaneous triad and high rates of BMF, patients with DC and related TBDs may have complex structural brain abnormalities, neurodevelopmental disorder, neuromotor impairment, and/or psychiatric diagnoses that can complicate their diagnosis and management. In a 2011 review of 118 patients with DC, features reported were developmental delay in 25%, ataxia/cerebellar hypoplasia in 7%, and microcephaly in 6%.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> We previously reported on 10 patients with DC and found that 70% had a primary psychiatric disorder and 30% had developmental delay.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> In our current study, we report structural brain abnormalities in addition to neurologic and psychiatric manifestations at higher frequencies than previously reported and that these phenotypes are associated with inheritance patterns, telomere length, and degree of BMF.</p>
<p>All patients with TBDs have very short telomeres for their age compared with unaffected individuals.<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R14">14</xref></sup> We found the shortest telomeres in patients with more structural brain findings and neurologic abnormalities than in patients with TBD with a normal brain MRI. Children with DC, HH, or RS and disease due to XLR or AR inheritance or de novo <italic>TINF2</italic> mutations were more likely to have CNS manifestations, including structural brain abnormalities (primarily cerebellar hypoplasia) and the associated microcephaly, neurodevelopmental disorder, and neuromotor findings, such as ataxia. These findings are consistent with previous studies suggesting more clinical complications in patients with TBDs due to recessive or <italic>TINF2</italic> disease and that these genetic etiologies result in exceedingly short telomeres.<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup> Notably, there were fewer abnormal brain MRI findings in adult patients with TBDs, possibly due to the fact that patients with AD TBDs often present as adults with isolated disease, such as pulmonary fibrosis or aplastic anemia.<sup><xref ref-type="bibr" rid="R17">17</xref></sup> It is notable that psychiatric disorders, including depression and anxiety, were present in 8 of the 18 (44%) adults, a rate higher than reported in the general population.<sup><xref ref-type="bibr" rid="R18">18</xref></sup></p>
<p>In comparison with the reported incidental findings on MRI in a general pediatric population, patients with DC, HH, or RS had higher frequencies of corpus callosum abnormalities, prominent cisterna magna, white matter lesions, and cavum septum pellucidum and/or cavum vergae.<sup><xref ref-type="bibr" rid="R16">16</xref></sup> Certain findings reported in the general population were not present in our cohort, likely because of its small sample size. For example, we had no patients with heterotopia, cortical dysplasia, agenesis of the septum pellucidum, or porencephalic cyst.</p>
<p>The role of telomere biology in brain development has been evaluated in a conditional knockout of the shelterin protein TRF2 mouse model.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> By knocking out TRF at different stages of neuronal differentiation, the authors showed that intact telomeres are essential for embryonic and adult neurogenesis. Specifically, TRF2 knockout resulted in uncapping of telomeres and a small dentate gyrus due to loss of granule cells in the hippocampus. However, conditional knockout of TRF2 in postmitotic neurons did not have an appreciable effect on cell function or animal behavior. Of interest, there are 5 reported cases of patients with HH and hypoplasia of the granular layer.<sup><xref ref-type="bibr" rid="R20">20</xref><xref ref-type="bibr" rid="R21">–</xref><xref ref-type="bibr" rid="R23">23</xref></sup></p>
<p>Our data support the hypothesis that aberrant telomere biology affects brain development, possibly through a combination of differences in neuronal connectivity and related structural differences. We also hypothesize that the cerebellum may be particularly vulnerable to aberrant telomere biology because it divides very early in development and for a longer time relative to other areas of the brain.<sup><xref ref-type="bibr" rid="R24">24</xref></sup> Because more cell divisions are required for cerebellar development and telomeres shorten with each cell division, it is possible that the cerebellar precursor cells in the fetus do not have the replicative capacity to proliferate normally due to exceedingly short telomeres in fetuses with DC, HH, and RS, thus explaining the relatively more common and more severe abnormalities in the cerebellum vs the less common, more minor anomalies in the cerebrum.</p>
<p>The current study is the first to systematically review brain MRIs in a series of patients with DC, HH, and RS. All brain MRIs were reviewed by the same neuroradiologist and the same subspecialty clinical teams evaluated the patients. An additional strength of our study is that MRIs were conducted independent of clinical indication, allowing for better estimates of the true prevalence of these findings in these disorders than has been previously reported. However, our study may not reflect the full spectrum of TBD-related neurologic complications because pediatric patients with especially severe manifestations are likely overrepresented in our study. A limitation of our study is that the brain MRIs varied in both quality and technique, as MRI technology advanced during the course of the study and images were acquired from several institutions. This lack of consistency may have led to the possibility of false negatives in some of the MRI reports, creating detection bias within our results. The data used in this study were cross-sectional; future studies involving prospective and longitudinal data are needed to further elucidate genotype-phenotype relationships in TBDs. Longitudinal MRI data are especially important when assessing delayed myelination<sup><xref ref-type="bibr" rid="R25">25</xref></sup>; cross-sectional studies of brain MRIs from older children and adults do not provide information about delayed myelination occurring during early development. Thus, the cross-sectional nature of our data did not allow us to estimate the prevalence of abnormal myelination in relation to developmental abnormalities in patients with TBDs. However, the high frequency of minor colpocephaly, which is associated with white matter abnormalities in the posterior cerebrum, suggests that white matter development may be affected<sup><xref ref-type="bibr" rid="R26">26</xref></sup> in patients with TBDs and needs to be further studied.</p>
<p>This study shows that structural brain abnormalities and clinically significant neurologic and psychiatric disorders are common in patients with TBDs. This report illustrates the need for research on the role of telomere biology in neurodevelopment. Comprehensive neurologic, neuropsychological, and psychiatric assessments and baseline brain MRI are indicated in patients with DC, HH, and RS to facilitate early referral to neurodevelopmental and mental health services.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors are grateful to thank all patients and their family members for making this work possible. They also thank the referring physicians, the MRI technologists who acquired the images, and Lisa Leathwood, RN, Maureen Risch, RN, and Ann Carr, CGC, of Westat, Inc. for clinical support.</p>
</ack>
<sec sec-type="contributions">
<title>Author contributions</title>
<p content-type="contributions">S. Bhala: study design, data collection, data analysis, data interpretation, and writing. A.F. Best: study design, data analysis, and writing. N. Giri: study design, data collection, data analysis, data interpretation, and writing. B.P. Alter: study design, data collection, data interpretation, and writing. M. Pao: data collection, data interpretation, and writing. A. Gropman and E.H. Baker: study design, data collection, data interpretation, and writing. S.A. Savage: study design, data collection, data analysis, data interpretation, and writing.</p>
</sec>
<sec sec-type="funding">
<title>Study funding</title>
<p content-type="funding">This work was funded by the Intramural Research Programs of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, the National Institute of Mental Health (ZIA MH002922-11), NIH, and the NIH Clinical Center.</p>
</sec>
<sec sec-type="disclosure">
<title>Disclosure</title>
<p content-type="disclosure">Disclosures available: <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e370/tab-article-info">Neurology.org/NG</ext-link>.</p>
</sec>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1">AD</term>
<def>
<p>autosomal dominant</p>
</def>
</def-item>
<def-item>
<term id="G2">AR</term>
<def>
<p>autosomal recessive</p>
</def>
</def-item>
<def-item>
<term id="G3">BMF</term>
<def>
<p>bone marrow failure</p>
</def>
</def-item>
<def-item>
<term id="G4">CI</term>
<def>
<p>confidence interval</p>
</def>
</def-item>
<def-item>
<term id="G5">DC</term>
<def>
<p>dyskeratosis congenita</p>
</def>
</def-item>
<def-item>
<term id="G6">
<italic>DSM</italic>
</term>
<def>
<p>
<italic>Diagnostic and Statistical Manual of Mental Disorders</italic>
</p>
</def>
</def-item>
<def-item>
<term id="G7">FISH</term>
<def>
<p>fluorescence in situ hybridization</p>
</def>
</def-item>
<def-item>
<term id="G8">IUGR</term>
<def>
<p>intrauterine growth restriction</p>
</def>
</def-item>
<def-item>
<term id="G9">OR</term>
<def>
<p>odds ratio</p>
</def>
</def-item>
<def-item>
<term id="G10">RS</term>
<def>
<p>Revez syndrome</p>
</def>
</def-item>
<def-item>
<term id="G11">TBD</term>
<def>
<p>telomere biology disorder</p>
</def>
</def-item>
<def-item>
<term id="G12">XLR</term>
<def>
<p>X-linked recessive</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name></person-group>
<article-title>Beginning at the ends: telomeres and human disease</article-title>. <source/>F1000Res
<year>2018</year>;<volume>7</volume>.</mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertuch</surname><given-names>AA</given-names></name></person-group>
<article-title>The molecular genetics of the telomere biology disorders</article-title>. <source/>RNA Biol
<year>2016</year>;<volume>13</volume>:<fpage>696</fpage>–<lpage>706</lpage>.<pub-id pub-id-type="pmid">26400640</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokal</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Vulliamy</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mason</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bessler</surname><given-names>M</given-names></name></person-group>
<article-title>Clinical utility gene card for: dyskeratosis congenita—update 2015</article-title>. <source/>Eur J Hum Genet
<year>2015</year>;<volume>23</volume>.</mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>PS</given-names></name></person-group>
<article-title>Cancer in dyskeratosis congenita</article-title>. <source/>Blood
<year>2009</year>;<volume>113</volume>:<fpage>6549</fpage>–<lpage>6557</lpage>.<pub-id pub-id-type="pmid">19282459</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Baerlocher</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita</article-title>. <source/>Blood
<year>2007</year>;<volume>110</volume>:<fpage>1439</fpage>–<lpage>1447</lpage>.<pub-id pub-id-type="pmid">17468339</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokal</surname><given-names>I</given-names></name></person-group>
<article-title>Dyskeratosis congenita</article-title>. <source/>Hematol Am Soc Hematol Educ Program
<year>2011</year>;<volume>2011</volume>:<fpage>480</fpage>–<lpage>486</lpage>.</mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vulliamy</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dokal</surname><given-names>I</given-names></name></person-group>
<article-title>Dyskeratosis congenita</article-title>. <source/>Semin Hematol
<year>2006</year>;<volume>43</volume>:<fpage>157</fpage>–<lpage>166</lpage>.<pub-id pub-id-type="pmid">16822458</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rackley</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Seratti</surname><given-names>GF</given-names></name>, <etal>et al</etal></person-group>
<article-title>Neuropsychiatric conditions among patients with dyskeratosis congenita: a link with telomere biology?</article-title>
<source/>Psychosomatics
<year>2012</year>;<volume>53</volume>:<fpage>230</fpage>–<lpage>235</lpage>.<pub-id pub-id-type="pmid">22458992</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study</article-title>. <source/>Br J Haematol
<year>2010</year>;<volume>150</volume>:<fpage>179</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">20507306</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>PS</given-names></name></person-group>
<article-title>Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up</article-title>. <source/>Haematologica
<year>2018</year>;<volume>103</volume>:<fpage>30</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">29051281</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="web"><collab>(CDC) CfDCaP</collab>. <article-title>Facts about microcephaly [online]</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/ncbddd/birthdefects/microcephaly.html">cdc.gov/ncbddd/birthdefects/microcephaly.html</ext-link>. Accessed July 2, 2018.</mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="book"><source/>Diagnostic and Statistical Manual of Mental Disorders. <publisher-loc>4th ed. Washington, DC</publisher-loc>: American Psychiatric Association, <year>2000</year>.</mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="book"><source/>Diagnostic and Statistical Manual of Mental Disorders, <edition>5th ed</edition>
<publisher-loc>Washington, DC</publisher-loc>: American Psychiatric Association, <year>2013</year>.</mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Baerlocher</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Lansdorp</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name></person-group>
<article-title>Telomere length is associated with disease severity and declines with age in dyskeratosis congenita</article-title>. <source/>Haematologica
<year>2012</year>;<volume>97</volume>:<fpage>353</fpage>–<lpage>359</lpage>.<pub-id pub-id-type="pmid">22058220</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Beyond the triad: inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita</article-title>. <source/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>:<fpage>804</fpage>–<lpage>806</lpage>.<pub-id pub-id-type="pmid">29042228</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Dremmen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>van den Berg</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Incidental findings on brain imaging in the general pediatric population</article-title>. <source/>N Engl J Med
<year>2017</year>;<volume>377</volume>:<fpage>1593</fpage>–<lpage>1595</lpage>.<pub-id pub-id-type="pmid">29045203</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savage</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name></person-group>
<article-title>Dyskeratosis congenita</article-title>. <source/>Hematology/oncology Clin North America
<year>2009</year>;<volume>23</volume>:<fpage>215</fpage>–<lpage>231</lpage>.</mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="web"><collab>Health NIoM</collab>. <article-title>Mental illness [online]</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nimh.nih.gov/health/statistics/mental-illness.shtml">nimh.nih.gov/health/statistics/mental-illness.shtml</ext-link>. Accessed January 20, 2019.</mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobanova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>She</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pieraut</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Clapp</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Maximov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Denchi</surname><given-names>EL</given-names></name></person-group>
<article-title>Different requirements of functional telomeres in neural stem cells and terminally differentiated neurons</article-title>. <source/>Genes Dev
<year>2017</year>;<volume>31</volume>:<fpage>639</fpage>–<lpage>647</lpage>.<pub-id pub-id-type="pmid">28428263</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoyeraal</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Lamvik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Moe</surname><given-names>PJ</given-names></name></person-group>
<article-title>Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers</article-title>. <source/>Acta Paediatr Scand
<year>1970</year>;<volume>59</volume>:<fpage>185</fpage>–<lpage>191</lpage>.<pub-id pub-id-type="pmid">5442429</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hreidarsson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kristjansson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Johannesson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Johannsson</surname><given-names>JH</given-names></name></person-group>
<article-title>A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure</article-title>. <source/>Acta Paediatr Scand
<year>1988</year>;<volume>77</volume>:<fpage>773</fpage>–<lpage>775</lpage>.<pub-id pub-id-type="pmid">3201986</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmood</surname><given-names>F</given-names></name>, <name name-style="western"><surname>King</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Smyth</surname><given-names>OP</given-names></name>, <name name-style="western"><surname>Farrell</surname><given-names>MA</given-names></name></person-group>
<article-title>Familial cerebellar hypoplasia and pancytopenia without chromosomal breakages</article-title>. <source/>Neuropediatrics
<year>1998</year>;<volume>29</volume>:<fpage>302</fpage>–<lpage>306</lpage>.<pub-id pub-id-type="pmid">10029349</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berthet</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Caduff</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>, <etal>et al</etal></person-group>
<article-title>A syndrome of primary combined immunodeficiency with microcephaly, cerebellar hypoplasia, growth failure and progressive pancytopenia</article-title>. <source/>Eur J Pediatr
<year>1994</year>;<volume>153</volume>:<fpage>333</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">8033921</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiemeier</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lenroot</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Greenstein</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pierson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Giedd</surname><given-names>JN</given-names></name></person-group>
<article-title>Cerebellum development during childhood and adolescence: a longitudinal morphometric MRI study</article-title>. <source/>Neuroimage
<year>2010</year>;<volume>49</volume>:<fpage>63</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">19683586</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branson</surname><given-names>HM</given-names></name></person-group>
<article-title>Normal myelination: a practical pictorial review</article-title>. <source/>Neuroimaging Clin N Am
<year>2013</year>;<volume>23</volume>:<fpage>183</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">23608684</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barkovich</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Lyon</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Evrard</surname><given-names>P</given-names></name></person-group>
<article-title>Formation, maturation, and disorders of white matter</article-title>. <source/>AJNR Am J Neuroradiol
<year>1992</year>;<volume>13</volume>:<fpage>447</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">1566710</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>